{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:56:40Z","timestamp":1791597400363,"version":"4.3.4"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,5,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      -mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 ). ANCHOR CRC aimed to evaluate efficacy, safety, and quality of life with first-line encorafenib + binimetinib + cetuximab in BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      -mutated mCRC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      In this multicenter, open-label, single-arm study, patients with BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      -mutated mCRC received oral encorafenib 300 mg once daily and binimetinib 45 mg twice daily in 28-day cycles, plus intravenous cetuximab 400 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      once on day 1 of cycle 1, then 250 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      once weekly for the first seven cycles, and 500 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      once on Days 1 and 15 from cycle 8 onward. The primary end point was locally assessed confirmed objective response rate (cORR), and secondary end points included centrally assessed cORR, progression-free survival, overall survival (OS), quality of life, and safety and tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 95 patients, the locally assessed cORR was 47.4% (95% CI, 37.0 to 57.9) with all partial responses. Since the lower limit of the 95% CI exceeded 30%, the primary end point was met. With a median follow-up duration of 20.1 months, the median progression-free survival on the basis of local assessments was 5.8 months and the median OS was 18.3 months. Treatment was well tolerated, with no unexpected toxicities. Using Patient Global Impression of Changes, substantial improvement in symptoms was consistently reported in \u2265 30% of patients from cycle 3 to cycle 10.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      The ANCHOR CRC study showed that the scientifically driven combination of encorafenib + binimetinib + cetuximab was active in the first-line setting of BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      -mutated mCRC with a manageable safety profile. Further first-line evaluation is ongoing (ClinicalTrails.gov identifier: NCT04607421 ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.22.01693","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:00:28Z","timestamp":1676044828000},"page":"2628-2637","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":88,"title":["ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated\n                    <i>BRAF<\/i>\n                    <sup>V600E<\/sup>\n                    -Mutant Metastatic Colorectal Cancer"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03693170","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"Eric","family":"Van Cutsem","sequence":"first","affiliation":[{"name":"University Hospital Leuven and KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology and Gastrointestinal Oncology, University Paris-cit\u00e9 (Paris Descartes), SIRIC CARPEM, Georges Pompidou European Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5454","authenticated-orcid":false,"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-6499","authenticated-orcid":false,"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[{"name":"West Cancer Center and Research Institute, Germantown, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-3435","authenticated-orcid":false,"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[{"name":"Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Elez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Institute of Oncology (VHIO), Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-3480","authenticated-orcid":false,"given":"Jeroen","family":"Dekervel","sequence":"additional","affiliation":[{"name":"University Hospital Leuven and KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-1886","authenticated-orcid":false,"given":"Paul","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guy's & St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruiz-Casado","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Graham","sequence":"additional","affiliation":[{"name":"Dept of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-320X","authenticated-orcid":false,"given":"Jose C.","family":"Ruffinelli","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u02caOncologia L\u02caHospitalet\u2013Hospital, Duran i Reynals, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Sorbonne University; Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Carri\u00e8re Roussel","sequence":"additional","affiliation":[{"name":"Pierre Fabre, Medical & Patient\/Consumer Division, Langlade, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Klauck","sequence":"additional","affiliation":[{"name":"Pierre Fabre, Medical & Patient\/Consumer Division, Boulogne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Groc","sequence":"additional","affiliation":[{"name":"Pierre Fabre, Medical & Patient\/Consumer Division, Langlade, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Vedovato","sequence":"additional","affiliation":[{"name":"Pierre Fabre, Medical & Patient\/Consumer Division, Langlade, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d\u2019Hebron Barcelona Hospital, Vall d\u2019Hebron Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70130-3"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605177"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131046"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.057"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.3511"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01798"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.023"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00122-9"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw261"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw272"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz208"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01994"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu260"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx738"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.5091"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3502"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2497"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0341"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1038\/nature10868"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2001148"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy149.026"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0795"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908075"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02459"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.080"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.014"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0915"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab042"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw645"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.01693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T18:01:37Z","timestamp":1683309697000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.01693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":29,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,5,10]]}},"alternative-id":["10.1200\/JCO.22.01693"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.01693","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"2022-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}